ArticleProceedings of the National Academy of Sciences of the United States of America2018
Tumor promoter TPA activates Wnt/β-catenin signaling in a casein kinase 1-dependent manner.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Expression of CSNK1D in lung adenocarcinoma and its prognostic value after surgery.Discover oncology · 2026Article
- Development of a Chemical Probe to Enable Characterization of the Casein Kinase 1γ Subfamily.Journal of medicinal chemistry · 2026Article
- Advances in the study of the relationship between neurotransmitters and gastric cancer.World journal of gastroenterology · 2025Review
- African spiny mice show resistance to DMBA/TPA-induced squamous carcinogenesis with distinct benign tumor profile.Protein & cell · 2025Article
- Inhibition of Casein Kinase 1International journal of molecular sciences · 2025Article
- Development of a chemical probe to enable characterization of the casein kinase 1γ subfamily.bioRxiv : the preprint server for biology · 2025Article
- Substrate displacement of CK1 C-termini regulates kinase specificity.Science advances · 2024Article
- Antimicrobial agent chloroxylenol targets β‑catenin‑mediated Wnt signaling and exerts anticancer activity in colorectal cancer.International journal of oncology · 2023Article
- The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis.eLife · 2023Article
- Article
- MCC is a centrosomal protein that relocalizes to non-centrosomal apical sites during intestinal cell differentiation.Journal of cell science · 2022Article
- Kinase domain autophosphorylation rewires the activity and substrate specificity of CK1 enzymes.Molecular cell · 2022Article
- CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes.Cancers · 2022Review
- CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders.Frontiers in molecular biosciences · 2022Review
- The CK1δ/ϵ-Tip60 Axis Enhances Wnt/β-Catenin SignalingFrontiers in oncology · 2022Article
- Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer.Cell death & disease · 2021Article
- 15d-PGJ2 inhibits NF-κB and AP-1-mediated MMP-9 expression and invasion of breast cancer cell by means of a heme oxygenase-1-dependent mechanism.BMB reports · 2020Article
- Method to Study Skin Cancer: Two-Stage Chemically Induced Carcinogenesis in Mouse Skin.Methods in molecular biology (Clifton, N.J.) · 2020Article
- IC261, a specific inhibitor of CK1δ/ε, promotes aerobic glycolysis through p53-dependent mechanisms in colon cancer.International journal of biological sciences · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Zijie SuGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Jiaxing SongGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Zhongyuan WangGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Liang ZhouGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Yuqing XiaGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Shubin YuGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Qi SunGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Shan-Shan LiuGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Liang ZhaoGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Shiyue LiGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China.
Lei WeiDepartment of Pathology and Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071 Hubei, China.
Dennis A CarsonGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China; dcarson@ucsd.edu delu@szu.edu.cn.
Desheng LuGuangdong Key Laboratory for Genome Stability & Disease Prevention, Carson International Cancer Center, Department of Pharmacology, Shenzhen University Health Science Center, Shenzhen, 518060 Guangdong, China; dcarson@ucsd.edu delu@szu.edu.cn.
Shenzhen University Health Science Center · CNWuhan University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor promoter 12-
Indexed as
AnimalsAxin Proteinbeta CateninCarcinogenesisCarcinogensCasein Kinase 1 epsilonCasein Kinase IdeltaCell Line, TumorDisease Models, AnimalFibroblastsHEK293 CellsHumansLow Density Lipoprotein Receptor-Related Protein-6MicePhosphorylationProtein StabilityAXIN1 protein, humanAxin Proteinbeta CateninCarcinogensCasein Kinase 1 epsilonCasein Kinase IdeltaCTNNB1 protein, humanLow Density Lipoprotein Receptor-Related Protein-6LRP6 protein, humanPurinesSR-3029TCF4 protein, humanTetradecanoylphorbol AcetateTranscription Factor 4Wnt ProteinsCK1LRP6TPAtwo-stage skin chemical carcinogenesisWnt/β-catenin signaling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.